New number of shares and votes in Moberg Pharma AB (publ)

New number of shares and votes in Moberg Pharma AB (publ)

Moberg Pharma AB (publ) (the "Company") today announces that the number of shares in the Company has increased to a total of 28,407,452 due to the completion of the rights issue of units, consisting of ordinary shares and warrants of series 2023:1, resolved by the Board of Directors on 28 June 2023 (the "Rights Issue") and due to the completion of the directed issue of units, consisting of ordinary shares and warrants of series 2023:1, to guarantors in the Rights Issue who chose to receive their guarantee commission in the form of units (the "Remuneration Issue").

The Rights Issue has entailed an increase in the number of shares and votes in the Company of 17,470,149 and the Remuneration Issue has entailed an increase in the number of shares and votes in the Company of 664,370. The total number of shares in Moberg Pharma AB (publ) thus amounts to 28,407,452 and the total number of votes amounts to 28,407,452 as of 29 September 2023, the last trading day of the month. All outstanding shares are ordinary shares.

At the date of this press release, the Company holds 445,974 own ordinary shares.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se

About this information
This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:30 am CEST on 29 September 2023 through the contact persons above.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).